© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
December 08, 2020
In preliminary findings from the ongoing first-in-human KOMET-001 trial, KO-539 showed activity in patients with relapsed or refractory acute myeloid leukemia.
December 07, 2020
Research presented at the 2020 ASH Annual Meeting may have found an alternative path forward for patients who do not respond to immunotherapy treatment for large B-cell lymphomas.
September 20, 2020
Apatinib in combination with gefitinib in the first-line setting demonstrated superior progression-free survival (PFS) in patients with advanced EGFR-mutant non–small cell lung cancer.
September 19, 2020
The first-in-class inhibitor of apoptosis protein (IAP) antagonist significantly improved overall survival in patients with LA-SCCHN.
Induction avelumab prior to standard of care led to a clinically relevant worsening of survival as the first-line treatment for patients with metastatic urothelial carcinoma.
June 03, 2020
Belantamab mafodotin monotherapy induced durable responses and appeared to be well tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.
November 11, 2019
Atezolizumab monotherapy improved overall survival compared with platinum-based chemotherapy as a first-line treatment in patients with wild-type non–small cell lung cancer with PD-L1 expression ≥50%.
PRS-343, a HER2/4-1BB targeting bispecific construct, is well-tolerated and demonstrated anti-tumor activity in heavily pre-treated patient population across multiple tumor types.